RET (E732K)

RET · Variant type: point · HGVS: p.E732K

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Pralsetinib	98.7%	1.3%	93.43
2	Fedratinib	98.5%	1.5%	96.21
3	Selpercatinib	98.3%	1.7%	96.72
4	Tivozanib	97.3%	2.7%	92.42
5	Gilteritinib	97.0%	3.0%	88.97
6	Vandetanib	93.8%	6.2%	95.74
7	Sunitinib	92.0%	8.0%	91.73
8	Entrectinib	91.8%	8.2%	93.69
9	Alpelisib	91.7%	8.3%	97.22
10	Tenalisib	88.7%	11.3%	97.98
11	Erdafitinib	88.3%	11.7%	95.71
12	Sorafenib	85.7%	14.3%	96.72
13	Ripretinib	80.4%	19.6%	92.95
14	Repotrectinib	74.2%	25.8%	84.21
15	Canertinib	72.4%	27.6%	96.49
16	Futibatinib	70.6%	29.4%	98.48
17	Apatinib	60.4%	39.6%	97.73
18	Defactinib	59.2%	40.8%	92.68
19	Quizartinib	50.9%	49.1%	99.50
20	Pexidartinib	46.9%	53.1%	99.49
21	Erlotinib	44.3%	55.7%	99.75
22	Lazertinib	35.8%	64.2%	97.47
23	Avapritinib	33.9%	66.1%	97.73
24	Pacritinib	26.1%	73.9%	88.64
25	Rabusertib	26.0%	74.0%	98.74

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Pralsetinib	98.7%	100.0%	-1.3%
Fedratinib	98.5%	99.9%	-1.3%
Selpercatinib	98.3%	100.0%	-1.7%
Tivozanib	97.3%	99.7%	-2.4%
Gilteritinib	97.0%	100.0%	-3.0%
Vandetanib	93.8%	98.6%	-4.8%
Sunitinib	92.0%	97.2%	-5.2%
Entrectinib	91.8%	99.6%	-7.8%
Alpelisib	91.7%	99.6%	-8.0%
Tenalisib	88.7%	98.5%	-9.8%
Erdafitinib	88.3%	94.7%	-6.3%
Sorafenib	85.7%	94.0%	-8.3%
Ripretinib	80.4%	—	—
Repotrectinib	74.2%	—	—
Canertinib	72.4%	—	—
Futibatinib	70.6%	97.7%	-27.1%
Apatinib	60.4%	—	—
Defactinib	59.2%	—	—
Quizartinib	50.9%	—	—
Pexidartinib	46.9%	—	—
Erlotinib	44.3%	—	—
Lazertinib	35.8%	—	—
Avapritinib	33.9%	—	—
Pacritinib	26.1%	—	—
Rabusertib	26.0%	—	—

Cancer	Organ	Source
carcinoma_lung	Lung	ref
carcinoma_thyroid	Thyroid	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.3ms